Menu Search
Equities

BioXcel Therapeutics Inc

BX2:DUS

BioXcel Therapeutics Inc

Actions
  • Price (EUR)0.6482
  • Today's Change0.043 / 7.11%
  • Shares traded300.00
  • 1 Year change-86.21%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 15:31 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in USDView more

In 2023, cash reserves at BioXcel Therapeutics Inc fell by 128.50m. Cash Flow from Financing totalled 26.52m or 1,921.88% of revenues. In addition the company used 155.01m for operations while cash used for investing totalled 20.00k.
Cash flow per share-3.31
Price/Cash flow per share--
Book value per share-1.84
Tangible book value per share-1.84
More ▼

Balance sheet in USDView more

BioXcel Therapeutics Inc appears to have a weak balance sheet, highlighted by its negative owner's equity. Additionally, this company's debt load outweighs its assets while day-to-day operations are losing money. One plus is that there are enough liquid assets to satisfy current obligations, however, this situation is unsustainable over the long run. BioXcel Therapeutics Inc has considerable financial risk.
Current ratio2.35
Quick ratio2.25
Total debt/total equity--
Total debt/total capital3.59
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.